FDA Accepts Review of Drug Application of Roflumilast Foam f

It was announced by Arcutis Biotherapeutics that the US Food and Drug Administration had accepted for review their NDA for roflumilast foam 0.3%.

Related Keywords

Arcutis Biotherapeutic , Neal Bhatia , Arcutis Biotherapeutics , Clinical Dermatology At Therapeutics Research , Drug Administration , Prescription Drug User Free Act , Clinical Dermatology , Therapeutics Clinical Research , Applied Topically , Investigator Global Assessment , New Drug Application , Roflumilast Foam , Seborrheic Dermatitis , Individuals Aged , Data Indicates Roflumilast Foam Helpful ,